An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients

References

• Coleman R. Metastatic bone disease;clinical features,pathophysiology and treatment strategies. Cancer Treat. 2001;27:165–176.
   Google Scholar
• Scheid V, Buzdar AU, Smith TL, et al. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986;58:2589–2593.
   PubMed Web of Science ®Google Scholar
• Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer. 1997;80(8 Suppl):1646–1651.
   PubMed Web of Science ®Google Scholar
• Perez JE, Machiavelli M, Leone BA, et al. Bone-only versus visceral-only metastatic pattern in breast cancer: analysisof 150 patients. A GOCS study. Am J Clin Oncol. 1990;13:294–298.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Younger J, Finkelstein DM, et al. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 2000;89:363–368.
   PubMed Web of Science ®Google Scholar
• Niikura N, Liu J, Hayashi N, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011;16:155–164.
   PubMed Web of Science ®Google Scholar
• Leone BA, Romero A, Rabinovich MG, et al. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The G.O.C.S. Experience. Am J Clin Oncol. 1988;11:618–622.
   PubMed Web of Science ®Google Scholar
• Schroder J, Fietz T, Kohler A, et al. TMK-Group (Tumour Registry Breast Cancer). Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer. 2017;79:139–148.
   PubMed Web of Science ®Google Scholar
• Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–3114.
   PubMed Web of Science ®Google Scholar
• Solomayer EF, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59:271–278.
   PubMed Web of Science ®Google Scholar
• Kaplan MA, Arslan UY, Işıkdogan A, et al. Biological subtypes and distant relapse pattern in breast cancer patients after curative surgery (Study of Anatolian Society of Medical Oncology). Breast Care. 2016;11:248–252.
   PubMed Web of Science ®Google Scholar
• Delpech Y, Bashour SI, Lousquy R, et al. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer. 2015;113:1003–1009.
   PubMed Web of Science ®Google Scholar
• Parkes A, Clifton K, Al-Awadhi A, et al. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018;25(4):2. eCollection 2018.
   Google Scholar
• Cardoso F, Costa A, Senkus E, et al. Rd ESO-ESMO ınternational consensus guidelines for advanced breast cancer. Ann Oncol. 2017;28:16–38.
   PubMed Web of Science ®Google Scholar
• Petrut B, Trinkaus M, Simmons C, et al. A primer of bone metastases management in breast cancer patients. Curr Oncol. 2008;15(Suppl 1):S50–7.
   PubMedGoogle Scholar
• Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57–62.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243–6249.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12(SDF-1)/CXR4 pathway in cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2010;16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Jin X, Malladi S, et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 2013;154:1060–1073.
   PubMed Web of Science ®Google Scholar
• Zheng H, Li W, Kang Y. Tumor-stroma interactions in bone metastasis: molecular mechanisms and therapeutic implications. Cold Spring Harb Symp Quant Biol. 2016;81:151–161.
   PubMedGoogle Scholar
• Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19:92–101.
   PubMed Web of Science ®Google Scholar
• Devita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenbergs cancer: principles & practice of oncology. 8th ed. Philadelphia, PA: Wolters Kluwer Health | Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Wong M, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press). 2011;3:35–60.
   PubMedGoogle Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–1867.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Breast Cancer 2017. [ cited 2018 Mar 25]. http://www.nccn.org/professionals/physician.gls/pdf/breast.pdf.
   Google Scholar
• Twelves C, Jove M, Gombos A, et al. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer. Crit Rev Oncol Hematol. 2016;100:74–87.
   PubMed Web of Science ®Google Scholar
• Fedele P, Calvani N, Marino A, et al. Targeted agents tor reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?. Crit Rev Oncol Hematol. 2012;84:243–251.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Rorive A, Collignon J. Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. Future Oncol. 2015;11:1775–1789.
   PubMed Web of Science ®Google Scholar
• Kamby C, Vestlev PM, Mouridsen HT. Site-specific effect of chemotherapy in patients with breast cancer. Acta Oncol. 1992;31:225–229.
   PubMed Web of Science ®Google Scholar
• Bonotto M, Gerratana L, Di Maio M, et al. chemotherapy versus endocrine therapy as first –line treatment in patients with luminal-like her2-negative metastatic breast cancer: a propensity score analysis. The Breast. 2017;31:114–120.
   PubMed Web of Science ®Google Scholar
• Stockler M, Wilcken NR, Ghersi D, et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26:151–168.
   PubMed Web of Science ®Google Scholar
• Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000;18:2395–2405.
   PubMed Web of Science ®Google Scholar
• Song Z, Deng P, Teng F, et al. Development on PEG-modified Poly(Amino Acid) Copolymeric Micelles for delivery of anticancer drug. Anticancer Agents Med Chem. 2017;17:784–801.
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced antracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13:2879–2885.
   PubMed Web of Science ®Google Scholar
• Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Refferral Center trial. J Clin Oncol. 1995;13:2056–2065.
   PubMed Web of Science ®Google Scholar
• Oostendorp LJ, Stalmeier PF, Donders AR, et al. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: asystematic review. Lancet Oncol. 2011;12:1053–1061.
   PubMed Web of Science ®Google Scholar
• Steger GG, Dominguez A, Dobrovolskaya N, et al. Single-Agent Oral Vinorelbine as first-line chemotherapy for endocrine-pretreated breast cancer with bone metastases and no visceral involvement: NORBREAST-228 Phase II Study. Clin Breast Cancer. 2018;18:41–47.
   Web of Science ®Google Scholar
• Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–493.
   PubMed Web of Science ®Google Scholar
• Gluck S, Russell C, O’Shaughnessy J, et al. Relationship between survival and estrogen receptor status in pts with metastatic breast cancer treated with capecitabine and docetaxel: anexploratory data analysis. Journal of Clinical Oncology. 2009;27(15S):Abstract 1024.
   Google Scholar
• Babacan T, Efe O, Hasirci AS, et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015;101:418–423.
   PubMed Web of Science ®Google Scholar
• Pajk B, Cufer T, Canney P, et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008;17:180–185.
   PubMed Web of Science ®Google Scholar
• O’shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phaseIII trial results. J Clin Oncol. 2002;20:2812–2823.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256–3263.
   PubMed Web of Science ®Google Scholar
• Twelves C, Nasim MY, Anthoney A et al. Effficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: anopen-label, phase II dose-comfirmation study.Presented at San Antonio Breast Cancer Symposium, 2014, San Antonio, TX, Poster P3-13-04.
   Google Scholar
• Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol. 2016;7:331–336.
   PubMedGoogle Scholar
• Arican A, Bozkurt T, Bozcuk H, et al. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014;22:2629–2634.
   PubMed Web of Science ®Google Scholar
• Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracyclinepretreated patients with metastatic breast cancer. J Clin Oncol. 2009;27:1753–1760.
   PubMed Web of Science ®Google Scholar
• Vici P, Capomolla E, Foggi P, et al. High activity of salvage treatment with biweekly paclitaxel –gemcitabine combination in heavily pretreated breast cancer patients. J Exp Clin Cancer Res. 2006;25:39–44.
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950–3957.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye G, Yan D, et al. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials. Oncotarget. 2017;8:72950–72958.
   PubMedGoogle Scholar
• Mahtani RL, Parisi M, Glück S, et al. Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. Cancer Manag Res. 2018;10:249–256.
   PubMed Web of Science ®Google Scholar
• Prestifilippo A, Grippaldi D, Blanco G, et al. Eribulin efficacy based on type of metastatic site: areal-life study in heavily pretreated metastatic breast cancer. Future Oncol. 2017;13:5–10.
   PubMed Web of Science ®Google Scholar
• Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. J Pharm Investig. 2012;2:2–11.
   Google Scholar
• Jiang B, Cao J, Zaho J, et al. Dual-targeting delivery system for bone cancer: synthesisand preliminary biological evaluation. Drug Deliv. 2012;19:317–326.
   PubMed Web of Science ®Google Scholar
• Chang Q, Geng R, Wang S, et al. DOPA-based paclitaxel-loaded liposomes with modifications of transferin and alendronate for bone and myeloma targeting. Drug Deliv. 2016;23:3629–3638.
   PubMed Web of Science ®Google Scholar
• Karacivi M, Sumer Bolu B, Sanyal R. Targeting to the bone: alendronate-directedcombretastatin A-4 bearing antiangiogenic polymerdrug conjugates. Mol Pharm. 2017;14:1373–1383.
   PubMed Web of Science ®Google Scholar
• Vinay R, Kusum Devi V. Potential of targeted drug delivery system for the treatment of bone metastasis. Drug Deliv. 2016;23:21–29.
   PubMed Web of Science ®Google Scholar
• El-Mabhouh AA, Nation PN, Abele JT et al. A conjugate of gemcitabine with bisposphonate (Gem/BP) shows potential as a targeted bone-spesific therapeutic agent in an animal model of human breast cancer bone metastases. Oncol Res. 2011;19:287–295.
   PubMed Web of Science ®Google Scholar
• Miller K, Clementi C, Polyak D, et al. Poly (ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials. 2013;34:3795–3806.
   PubMed Web of Science ®Google Scholar
• Ye WL, Zhao YP, Li HQ, et al. Doxorubicin-poly(ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Sci Rep. 2015;5:14614.
   PubMed Web of Science ®Google Scholar
• Murphy MB, Hartgerink JD, Goepferich A, et al. Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding of peptides conjugated to calcium-binding moieties. Biomacromolecules. 2007;8:2237–2243.
   PubMed Web of Science ®Google Scholar
• Leamon P, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127–1141.
   PubMed Web of Science ®Google Scholar
• Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396–3401.
   PubMed Web of Science ®Google Scholar
• Ke X, Lin W, Li X, et al. Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer. Drug Deliv. 2017;24:1680–1689.
   PubMed Web of Science ®Google Scholar
• Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: canmetastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456–463.
   PubMedGoogle Scholar
• Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: bone metastases in breast cancer patients. Oncol Lett. 2013;6:306–310.
   PubMed Web of Science ®Google Scholar
• Ahn SG, Lee HM, Cho S, et al. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J. 2013;54:1168–1177.
   PubMed Web of Science ®Google Scholar
• Koizumi M, Yoshimoto M, Kasumi F, et al. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol. 2003;14:1234–1240.
   PubMed Web of Science ®Google Scholar
• Dellas K. Does radiotherapy have curative potential in metastatic patients? The concept of local therapy in oligometastatic breast cancer. Breast Care. 2011;6:363–368.
   PubMed Web of Science ®Google Scholar
• Lascio SD, Pagani O. O ligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care. 2014;9:7–14.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparisonof clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.
   PubMedGoogle Scholar
• Makatsoris T, Kalofonos HP. The role of chemotherapy in the treatment of bone metastases. Bone Metastases. 2009;12:287–298.
   Google Scholar
• Yan M, Song ST, Jiang ZF, et al. Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer. Zhonghua Zhong Liu Za Zhi. 2004;26:177–180.
   PubMedGoogle Scholar
• Di Leo A, Curigliano G, Dieras V, et al. New approaches for improving outcomes in breast cancer in Europe. The Breast. 2015;24:321–330.
   PubMed Web of Science ®Google Scholar
• Campone M, Bachelot T, Gnant M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroupanalysis from the BOLERO-2 study. Eur J Cancer. 2013;49:2621–2632.
   PubMed Web of Science ®Google Scholar
• Gnant M, Baselga J, Rugo HS, et al. of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105:654–663.
   PubMed Web of Science ®Google Scholar
• Turner N, Turner NC, Ro J, et al. PALOMA-33 Study Group. Palbociclib in hormone-receptor positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Finn R, Martin M, Rugo HR, et al. PALOMA-2: primary results from a phase III trial of palbociclib(P) with letrozole(L) compared with letrozole alone in postmenopausal women with ER+/HER2 –advanced breast cancer(ABC). J Clin Oncol. 2016;34(Suppl):Abstract 507.
   Google Scholar
• Coleman R, Gnant M, Morgan G, et al. Effects of bone targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012;104:1059–1067.
   PubMed Web of Science ®Google Scholar
• Hiraga T. Targeted agents in preclinical and early clinical development for the treatment of cancer bone metastases. Expert Opin Investig Drugs. 2016;25:319–334.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon DH, Jr DW, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893–2897.
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Evans CA, Coleman RE, et al. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006;27:92–103.
   PubMed Web of Science ®Google Scholar
• Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082–1090.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. protocol 19 aredia breast cancer study group. J Clin Oncol. 1998;16:2038–2044.
   Google Scholar
• Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: finalefficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014 Aug;15(9):997–1006.
   PubMed Web of Science ®Google Scholar
• Yan T, Yin W, Zhou Q, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer. 2012;48:187–195.
   PubMed Web of Science ®Google Scholar
• Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365:1396–1405.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: arandomized,double-blind study. J Clin Oncol. 2010;28:5132–5139.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, et al. phase II trial of denosumab in patients with bone metastases from prostate cancer,breast cancer or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–1571.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Aug 1;386(9992):433–443.
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Guenther GS, et al. Adjuvant denosumab in early breast cancer: disease-freesurvival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.2018 ASCO Annual Meeting.Abstract No: 500. J Clin Oncol. 2018;36.
   Google Scholar
• Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer.First results from the international multicenter randomized phase III placebo controlled D-CARE study. 2018 ASCO Annual Meeting. Abstract No:501. J Clin Oncol. 2018;36.
   Google Scholar
• Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017;36(1):108.
   PubMedGoogle Scholar
• Klijn JG, Berns PM, Schmitz PI, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: areview on 5232 patients. Endocr Rev. 1992;13:3–17.
   PubMed Web of Science ®Google Scholar
• Normanno N, Gullick W. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: differentmechanisms of action for a novel therapeutic application? Endocr-Relat Cancer. 2006;13:3–6.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lee FY, Bhalla KN, et al. Potent inhibition of platelet –derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527–1533.
   PubMed Web of Science ®Google Scholar
• Llombart A, Strauss AR, Sy LO, et al. PD01-02:randomizedphase II study of dasatinib vs plasebo in addition to exemestane in advanced ER/PR-positive breast cancer (BMS CA 180-261 Study). Cancer Res. 2011;71:24.
   Web of Science ®Google Scholar
• Dasatinib-letrozole gets slit verdict. Cancer Discov. 2014;4:138–139.
   Web of Science ®Google Scholar
• Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: resultsof a 4-week,double-blind,randomized,controlled. Trial Clin Breast Cancer. 2010;10:452–458.
   PubMed Web of Science ®Google Scholar
• Bauerle T, Hilbig H, Bartling S, et al. Bevacizumab inhibits breast cancer-induced osteolysis,surrounding sof tissue metastasis and angiogenesis in rats as visualized VCT and MRI. Neoplasia. 2008;10:511–520.
   PubMed Web of Science ®Google Scholar
• Bachelier R, Confavreux CB, Peyruchaud O, et al. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int J Cancer. 2014;135:1319–1329.
   PubMed Web of Science ®Google Scholar
• Brook N, Brook E, Dharmarajan A, et al. Breast cancer bone metastases: pathogenesisand therapeutic targets. Int J Biochemistry Biol. 2018;96:63–78.
   PubMed Web of Science ®Google Scholar
• Makhoul I, Atiq M, Alwbari A, et al. Breast Cancer Immunotherapy: an Update. Breast Cancer (Auckl). 2018;3012:11782234–18774802. eCollection 2018
   Google Scholar
• Hu ZI, McArthur HL. Immunotherapy in breast cancer: the new Frontier.Curr Breast Cancer Rep. 2018;10:35–40.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16:3485–3494.
   PubMed Web of Science ®Google Scholar
• Rugo H, J-P D, S-A I, et al. Abstract S5-07: preliminary efficacy and safety of pembrolizumab(MK-3475) in patients with PD-L1-positive,estrogen receptor-positive (ER+)/HER2 –negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 2016;76:S5-07-S5.
   Web of Science ®Google Scholar
• Reinstein ZZ, Pamarthy S, Sagar V, et al. Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol. 2017;117:114–127.
   PubMed Web of Science ®Google Scholar